|
|
Post by sportsrancho on Dec 15, 2020 19:40:40 GMT -5
Re: Mike's comment that TreT royalties would start in Q4 2022, this made no sense to me so I reached out to MNKD. Mike clarifed that he intended to say the revenue stream would begin Q4 2021 to Q1 2022. Did he clarify that for everyone that was listening to the presentation🤦🏼‍♀️ Actually that was my assumption because we should have approval in November 2021. Thanks so much for clarifying❣️ |
|
|
|
Post by neil36 on Dec 15, 2020 20:39:43 GMT -5
Re: Mike's comment that TreT royalties would start in Q4 2022, this made no sense to me so I reached out to MNKD. Mike clarifed that he intended to say the revenue stream would begin Q4 2021 to Q1 2022. Thank you RonW. I was sure he misspoke. But the unsettling thing was that he said it like three times in less than two minutes. Thanks for getting him to clarify that important point. |
|
|
|
Post by geomean on Dec 16, 2020 0:29:09 GMT -5
Mike also confirmed current (about $500M) and projected sales (towards 1B) of TreT so at low double digit royalty add around $50M at 10% (or somewhat more) growing to maybe $100M (or more) in royalty revenue looking out towards 2022 to 2025 plus profit on Danbury production. As an aside the $TRx for the most recent week reported on the Mannkind Proboards script #’s page here is $1.6M and the chart provided suggests Afrezza sales are trending generally higher. Mike indicated that Q4 is usually a strong quarter for sales. With the $12.5 milestone payment plus the Afrezza sales increase, the Q4 revenue comparison might approach an 80% - 100% increase YOY. The slide showing the 5 analysts and their price projections going as high as $4 fits the recent stock price action, which appears to be a breakout above some significant prior intermediate term highs after a long period building a base. A simple AB=CD zig zag projection suggests the current thrust has further to go. A DeMark analysis also suggests further upward movement.
|
|
|
|
Post by boca1girl on Dec 16, 2020 9:58:10 GMT -5
Re: Mike's comment that TreT royalties would start in Q4 2022, this made no sense to me so I reached out to MNKD. Mike clarifed that he intended to say the revenue stream would begin Q4 2021 to Q1 2022. Wow, that’s a big clarification! |
|
|
|
Post by goyocafe on Jan 21, 2021 5:34:43 GMT -5
|
|
|
|
Post by prcgorman2 on Jan 21, 2021 7:23:01 GMT -5
My opinion is CEOs like Dr. Castagna do not engineer the acquisition of companies like Qrumpharma. If we had seen a pattern of acquisition under Dr. Castagna, it would be a reasonable speculation. I suppose acquiring Qrumpharma could be a start of a pattern but it cannot be argued it is an established pattern. So, I assume it was a business decision and had the approval and perhaps direction from the Board of Directors as part of a strategy associated with continuing development of the TS franchise. That is, after all, what they claimed.
|
|
|
|
Post by porkini on Jan 21, 2021 7:45:17 GMT -5
My opinion is CEOs like Dr. Castagna do not engineer the acquisition of companies like Qrumpharma. If we had seen a pattern of acquisition under Dr. Castagna, it would be a reasonable speculation. I suppose acquiring Qrumpharma could be a start of a pattern but it cannot be argued it is an established pattern. So, I assume it was a business decision and had the approval and perhaps direction from the Board of Directors as part of a strategy associated with continuing development of the TS franchise. That is, after all, what they claimed. Original press release for this acquisition ( mnkd.proboards.com/post/214232/thread): " Locust Walk served as an advisor to MannKind." Original press release for Locust Walk: mnkd.proboards.com/post/109988/thread |
|
|
|
Post by geomean on Jan 21, 2021 12:23:17 GMT -5
Those were helpful links. They suggest to me that Revimmune Novoteris, LLC Insmed Incorporated Savara Inc. are all focusing on the oral administration of new forms of Clofazimine, often as part of a multi-drug/molecule approach. The logic for the Qrumpharma Mannkind combination is largely based on the increased activity resulting from the direct delivery of Clofazimine to the lungs as set out in the Conclusion section of this Qrumpharma presentation of www.qrumpharma.com/NACFC%20Conference%20Poster%202018-10-12.pdf. Of course, the Technosphere system can also accommodate multi-drug/molecules giving it a leg up where inhaled formulations are more efficient. “QRM-003 was generally well tolerated across all time-points and pulmonary epithelial cells investigated. Clofazimine from QRM-003 maintains the ability to be taken-up by a macrophage cell line – this is important for activity against intracellular NTM infection. QRM-003 demonstrated the greatest antimycobacterial activity against both M. avium and M. abscessus in all models investigated. This increased activity was significantly improved compared to oral administration of clofazimine.”
|
|
|
|
Post by goyocafe on Jan 21, 2021 14:02:01 GMT -5
Those were helpful links. They suggest to me that Revimmune Novoteris, LLC Insmed Incorporated Savara Inc. are all focusing on the oral administration of new forms of Clofazimine, often as part of a multi-drug/molecule approach. The logic for the Qrumpharma Mannkind combination is largely based on the increased activity resulting from the direct delivery of Clofazimine to the lungs as set out in the Conclusion section of this Qrumpharma presentation of www.qrumpharma.com/NACFC%20Conference%20Poster%202018-10-12.pdf. Of course, the Technosphere system can also accommodate multi-drug/molecules giving it a leg up where inhaled formulations are more efficient. “QRM-003 was generally well tolerated across all time-points and pulmonary epithelial cells investigated. Clofazimine from QRM-003 maintains the ability to be taken-up by a macrophage cell line – this is important for activity against intracellular NTM infection. QRM-003 demonstrated the greatest antimycobacterial activity against both M. avium and M. abscessus in all models investigated. This increased activity was significantly improved compared to oral administration of clofazimine.”
Thanks for pointing this out. |
|
|
|
Post by celo on Jan 21, 2021 17:34:29 GMT -5
Mike also confirmed current (about $500M) and projected sales (towards 1B) of TreT so at low double digit royalty add around $50M at 10% (or somewhat more) growing to maybe $100M (or more) in royalty revenue looking out towards 2022 to 2025 plus profit on Danbury production. As an aside the $TRx for the most recent week reported on the Mannkind Proboards script #’s page here is $1.6M and the chart provided suggests Afrezza sales are trending generally higher. Mike indicated that Q4 is usually a strong quarter for sales. With the $12.5 milestone payment plus the Afrezza sales increase, the Q4 revenue comparison might approach an 80% - 100% increase YOY. The slide showing the 5 analysts and their price projections going as high as $4 fits the recent stock price action, which appears to be a breakout above some significant prior intermediate term highs after a long period building a base. A simple AB=CD zig zag projection suggests the current thrust has further to go. A DeMark analysis also suggests further upward movement. So they burn about 12 million a quarter and will be receiving 50 million in royalties/year starting in 2022. Seems like MNKD won't be burning through cash for more than a year, or at least at that point it will be pretty minimal. |
|
|
|
Post by mango on Jul 7, 2021 7:38:46 GMT -5
|
|
|
|
Post by Clement on Jul 7, 2021 8:04:53 GMT -5
So far, MNKD-101 (clofazimine) is administered as an aerosol by nebulizer, right?
Has anyone heard about a possible clofazimine DPI utilizing Technosphere?
|
|
|
|
Post by mango on Jul 7, 2021 8:09:55 GMT -5
So far, MNKD-101 (clofazimine) is administered as an aerosol by nebulizer, right? Has anyone heard about a possible clofazimine DPI utilizing Technosphere? I believe MC mentioned this in a call. I think he said something to the effect of they would be exploring feasibility studies with Clofazimine for Technosphere DPI. I’m actually more curious as to WHO MannKind will partner with for the nebulizers if they go that route. May we see a BP partnership soon? |
|
|
|
Post by sportsrancho on Jul 7, 2021 8:27:07 GMT -5
|
|
|
|
Post by mango on Jul 7, 2021 9:39:22 GMT -5
I suspect we will see another announcement come out before clofazimine Phase 1 initiation due to the simple fact that if MannKind does go forward with the nebulizer formulation, they will need to use the intended nebulizer for commercial sales and thus need that nebulizer used in clinical trials for the NDA packet and FDA approval.
Of course, MannKind may decide to develop their own, but I have not heard any mention of that possibility yet.
|
|
